PROCESS FOR MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS IN A SUBJECT

The method for the manufacture of a composition for the treatment of osteoarthritis in subjects involves the use of mesenchymal stem cells (MSC). These MSCs are derived from at least two healthy donors who are different from the subject to be treated. The MSCs are morphologically healthy and substan...

Full description

Saved in:
Bibliographic Details
Main Authors SZUKACSOV, Valéria, KRISTON-PÁL, Éva
Format Patent
LanguageEnglish
Published 30.05.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The method for the manufacture of a composition for the treatment of osteoarthritis in subjects involves the use of mesenchymal stem cells (MSC). These MSCs are derived from at least two healthy donors who are different from the subject to be treated. The MSCs are morphologically healthy and substantially free of senescent cells. They are also free of pathogens characteristic of the species and possess the main characteristics of MSCs. During propagation, the cumulative population doubling value (CPD value) of the MSCs is preferably in the range of 3 to 14. The level of kynurenine metabolite production of the MSCs is in the range of 30 to 50 ng/ml, and the level of THBS1 cytokine production of the MSCs is in the range of 50 to 80 ng/ml. The number of cells used is in the range of 105 to 5×107.
Bibliography:Application Number: US202218284831